Benitec生物製藥 BNTC 深 滬
等待開盤 09-26 09:30:00 美东时间
13.80
-0.290
-2.06%
華盛通- 最 高14.3311
- 今 開14.01
- 成交量 3.53万股
- 最 低 13.59
- 昨 收 14.09
- 總市值 3.62亿
- 52周最高 17.15
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 9.09
- 委 比 6.98%
- 總股本 2625.05万
- 歷史最高 5609.5744
- 量 比 0.53
- 振 幅 5.26%
- 歷史最低 2.227
- 每 手 1
- 風險率 1.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $20 Price Target
JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and maintains $20 price target.
09-24 21:02
Benitec报告GAAP每股收益为-1.05美元
Benitec公司（NASDAQ：BNTC）报告GAAP每股收益为-1.05美元，而预期为每股收益0.72美元。截至2025年6月30日，该公司持有977...
09-23 23:22
Benitec GAAP EPS of -$1.05 beats by $0.72
Benitec press release (NASDAQ:BNTC): FY GAAP EPS of -$1.05 beats by $0.72. As of June 30, 2025, the company had $97.7 million in cash and cash equivalents. More on Benitec Seeking Alpha’s Quant Rating...
09-23 12:48
Benitec Biopharma Reports 2025 Financial Results and Progress
Benitec Biopharma ( ($BNTC) ) has released its Q4 earnings. Here is a breakdown...
09-23 11:52
Benitec Biopharma files $200M mixed securities shelf
Benitec Biopharma (NASDAQ:BNTC) filed $200M mixed securities shelf. Filing More on Benitec Seeking Alpha’s Quant Rating on Benitec Financial information for Benitec
09-23 05:27
Benitec Biopharma Q4 EPS $0.00 Beats $(0.33) Estimate
Benitec Biopharma (NASDAQ:BNTC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.33) by 100.3 percent. This is a 100.17 percent increase over losses of $(0.60) per share
09-23 04:08
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
Oppenheimer Maintains Outperform on Benitec Biopharma, Lowers Price Target to $29
Oppenheimer analyst Andreas Argyrides maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and lowers the price target from $35 to $29.
09-16 23:56
